Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pharmaceuticals

News provided by

Feb 20, 2017, 20:28 ET

NEW YORK, Feb. 20, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Read the full report: http://www.reportlinker.com/p04707122-summary/view-report.html

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 27 companies including many key and niche players such as:
- Alcobra Ltd.
- Amarantus Bioscience Holdings, Inc.
- Amedra Pharmaceuticals LLC
- Curemark, LLC.
- Eli Lilly and Company

Read the full report: http://www.reportlinker.com/p04707122-summary/view-report.html

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW.............. II-1 ADHD Therapeutics: A Primer..............II-1 ADHD Therapeutics Market Outlook II-1 Factors Driving ADHD Therapeutics Market II-1 Changes in Insurance Coverage II-1 Addition of Formal Guidelines II-2 Low Diagnosis Threshold..............II-2 Advancements in Field of Medicine II-2 Unmet Needs.............. II-2 Launch of Pipeline Drugs..............II-2 Factors Inhibiting ADHD Therapeutics Market II-2 Side Effects Related to Use of Stimulants to Treat ADHD II-3 Under-diagnosis of ADHD Condition II-3 Reduced Availability of Non-Stimulants in Certain Geographies II-3 Competitive Landscape..............II-3 Major ADHD Medications Available in the Market II-4 ADHD Medications Approved by FDA II-4 Patent Validity for Major ADHD Drugs II-4

2. NOTEWORTHY TRENDS IN ADHD THERAPEUTICS MARKET II-5 Biological Psychiatry Gaining Ground II-5 Social Media Drives Heightened Awareness II-5 Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity..............II-5 Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market.............. II-5 Strategic Alliances.............. II-6

3. DEVELOPMENTAL PIPELINE OF ADHD DRUGS II-7 An Overview.............. II-7 ADHD Drugs under Phase II/III Development in (2015) II-8

4. ADHD - AN INSIGHT.............. II-9 Attention Deficit Hyperactivity Disorder (ADHD) - Introduction II-9 Brief History of the Disorder..............II-9 Common Co-Occurring Disorders with ADHD II-9 Consequences of ADHD..............II-10 What Leads to ADHD?.............. II-10 Study Reveals Deficits in Protein Levels in Brain's Reward/ Motivation System..............II-10 ADHD Symptoms.............. II-10 Different Diagnostic Criteria for ADHD Diagnosis II-11 Overview of the ICD-10 medical classification system for ADHD II-11 ICD-10 Criteria for Diagnosing ADHD II-11 Diagnostic Guidelines..............II-12 ICD-10 Code for Diagnosing Hyperkinetic Disorder II-12 F90.0 Disturbance of activity and attention II-12 DSM Criteria for Diagnosis of ADHD II-12 DSM IV Criteria for ADHD Diagnosis II-12 DSM IV Criteria for Inattention and Hyperactivity/Impulsivity II-13 DSM 5™ Criteria.............. II-13 DSM-5™ DIAGNOSTIC CRITERIA FOR ADHD II-14 Inattention.............. II-14 Hyperactivity and Impulsivity II-14 Treating ADHD.............. II-15 Stimulants.............. II-15 Non-stimulants.............. II-15 Others.............. II-15 Alternative Treatments..............II-15 Overview of ADHD Treatment Options II-16 Risks Associated with Pharmacotherapy II-16

5. CLINICAL TRIALS.............. II-17 Supernus Announces Positive Results from Phase IIB Trials for SPN-812.............. II-17 Sunovion Announces Top-line Results from Phase II/III Clinical Trial.............. II-17 Taisho Conducts Phase II Trial for TS-141 II-17 Shire Announces Positive Top-Line Result from Phase III Trial of SHP465-305.............. II-17 Highland Therapeutics Initiates Phase II Trial for HLD100 II-17 FDA Advises Hold for Alcobra Phase III Trial MDX for ADHD II-17

6. PRODUCTS INNOVATIONS/INTRODUCTIONS II-18 Mylan Rolls Out Dextroamphetamine Sulphate Extended Release Capsules.............. II-18 Tris Pharma Introduces Liquid DYANAVEL XR for ADHD II-18 Neos Introduces Adzenys XR-ODT II-18 Shire Introduces Intuniv, Non-Stimulant Treatment for ADHD II-18 Shire Introduces Elvanse Adult®, Stimulant Treatment for Adult ADHD.............. II-18 Teva Adds Generic Intuniv® to Existing Line of ADHD Products II-18 FDA Approves Pfizer's QuilliChew ER™ Chewable Tablets II-19 Actavis Introduces Generic Version of Intuniv II-19

7. RECENT INDUSTRY ACTIVITY..............II-20 Shire Files New Drug Application for Chewable Vyvanse II-20 Medgenics Acquires neuroFix Therapeutics II-20

8. FOCUS ON SELECT GLOBAL PLAYERS..............II-21 Alcobra Ltd. (Israel)..............II-21 Amarantus Bioscience Holdings, Inc. (US) II-21 Amedra Pharmaceuticals LLC (US)..............II-21 Curemark, LLC. (US).............. II-22 Eli Lilly and Company (US)..............II-22 Intellipharmaceutics International, Inc. (US) II-22 Janssen Global Services, LLC (US) II-23 Mallinckrodt PLC (Ireland)..............II-23 Mylan N.V. (The Netherlands)..............II-23 Neos Therapeutics, Inc. (US)..............II-24 Neurovance, Inc. (US)..............II-24 Noven Pharmaceuticals, Inc. (US) II-24 Pfizer Inc. (US).............. II-25 Shire plc (Ireland).............. II-25 Supernus Pharmaceuticals, Inc. (US) II-25 Tris Pharma, Inc. (US)..............II-26

9. GLOBAL MARKET PERSPECTIVE..............II-27 Table 1: World Recent Past, Current & Future Analysis for ADHD Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-27

Table 2: World Historic Review for ADHD Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-28

Table 3: World 14-Year Perspective for ADHD Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-29

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 US ADHD Therapeutics Market Set Firmly on Growth Trajectory III-1 Table 4: US ADHD Market: Prices of Select ADHD Drugs (2015) (includes corresponding Graph/Chart) III-1 US ADHD Prevalence Rate: Some Major Facts III-2 Table 5: ADHD with Co-existing Conditions (includes corresponding Graph/Chart)..............III-2 Major Trends Impacting the US ADHD Therapeutics Market III-3 Generics Ruling the Roost in US ADHD Therapeutics Market III-3 Table 6: US Market for ADFHD Drugs: Percentage Breakdown of Revenue for Stimulants and Non-stimulants (2015) (includes corresponding Graph/Chart) III-3 Major ADHD drugs being sold in US market III-3 Adults on the Radar of US ADHD Drugs Manufacturers III-4 Table 7: US ADHD Drugs Market: Percentage Breakdown of ADHD Drug Prescriptions by Age Group & Gender (2015) (includes corresponding Graph/Chart) III-4 ADHD Drug for Adults: A Trail of Misuse, Addiction and Death III-4 More Prescriptions, More Issues III-5 Table 8: US ADHD Drugs Market: Prescriptions Filled (2010-2015) (includes corresponding Graph/Chart) III-5 More Drugs, More Complications, More Emergency Room Visits III-5 Though Small in Number, Deaths Due to ADHD Drug Complications is Rising..............III-6 ADHD in Children: A Case of One Diagnosis Too Many III-6 Individual Choices of Healthcare Professionals Influencing ADHD Diagnosis..............III-6 States Working with Federal Agencies to Tackle the Problem III-7 Arkansas: A Case Study in Rectifying the Over Diagnosis Problem.............. III-7 DSM 5™ Criteria.............. III-8 DSM-5™ DIAGNOSTIC CRITERIA FOR ADHD III-8 Inattention.............. III-8 Hyperactivity and Impulsivity III-9 Clinical Trials.............. III-9 Products Launches.............. III-10 Strategic Corporate Developments III-11 Select Major Players..............III-11 B.Market Analytics..............III-16 Table 9: The US Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-16

Table 10: The US Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-17

2. CANADA.............. III-18 A.Market Analysis.............. III-18 Current & Future Analysis..............III-18 Strategic Corporate Development III-18 B.Market Analytics..............III-18 Table 11: Canadian Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-18

Table 12: Canadian Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-19

3. JAPAN.............. III-20 A.Market Analysis.............. III-20 Increased Awareness Leading to Surge in Japanese ADHD Therapeutic Market..............III-20 Select ADHD Drugs in Pipeline in Japanese Market III-20 Strategic Corporate Development III-20 B.Market Analytics..............III-21 Table 13: Japanese Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-21

Table 14: Japanese Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-22

4. EUROPE.............. III-23 A.Market Analysis.............. III-23 Effective therapeutics and Rising Awareness Amongst Public Propelling European ADHD Market III-23 UK ADHD Market - An Overview III-23 ADHD Prevalence..............III-23 Table 15: ADHD Prevalence in the UK: Percentage Breakdown by Gender (Fiscal Year 2009-2010 through 2014-2015) III-24 Strategic Corporate Developments III-24 Select Key Players..............III-25 B.Market Analytics..............III-26 Table 16: European Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-26

Table 17: European Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-27

5. ASIA-PACIFIC.............. III-28 A.Market Analysis.............. III-28 Asia-Pacific ADHD Therapeutics Market on the Rise III-28 B.Market Analytics..............III-28 Table 18: Asia-Pacific Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-28

Table 19: Asia-Pacific Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-29

6. LATIN AMERICA.............. III-30 A.Market Analysis.............. III-30 Latin American ADHD Therapeutics Market to Cross US$3 billion III-30 B.Market Analytics..............III-30 Table 20: Latin American Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-30

Table 21: Latin American Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-31

7. REST OF WORLD.............. III-32 A.Market Analysis.............. III-32 Current & Future Analysis..............III-32 ADHASA Enabling South African Children with ADHD to Chart New Course.............. III-32 Strategic Corporate Development III-33 Alcobra Ltd. (Israel) - A Key Israeli Player III-33 B.Market Analytics..............III-34 Table 22: Rest of World Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-34

Table 23: Rest of World Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-35

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 27 (including Divisions/Subsidiaries - 28)

The United States (17) Canada (2) Japan (2) Europe (5) - The United Kingdom (1) - Rest of Europe (4) Middle East (2)
Read the full report: http://www.reportlinker.com/p04707122-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001